Pharmaceuticals

Pneumovax 23 Market Outlook 2026–2035: Growth Drivers and Industry Forecast

March 6, 2026March 8, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pneumovax 23 market from 2026–2035 with trusted insights from The Business Research Company

How is the Pneumovax 23 Market size predicted to change over the forecast window of 2026–2035?

The historical growth can be attributed to several factors, including the expansion of national immunization directives, a rising occurrence of pneumococcal infections among older populations, the accessibility of polysaccharide vaccines, an increase in preventive healthcare programs, and enhanced awareness regarding vaccination.

The projected growth during the forecast period is driven by several factors, including heightened investments in adult vaccination efforts, an intensified focus on averting infectious diseases, the expansion of immunization services provided by pharmacies, increasing requirements for sustained vaccine protection, and ongoing progress in vaccine storage and distribution methods. Furthermore, significant trends anticipated for the forecast period encompass an amplified focus on immunization programs for adults and older populations, a growing necessity for preventing pneumococcal diseases, the wider embrace of proactive vaccination strategies, an increase in public health immunization campaigns, and refined management of the vaccine cold chain.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20333&type=smp

Which Drivers Are Contributing To The Expansion Of The Pneumovax 23 Market?

The growing occurrence of pneumococcal diseases is set to boost the expansion of the Pneumovax 23 market. These diseases originate from the bacterium streptococcus pneumoniae, or pneumococcus, leading to a spectrum of health problems, from mild cases like sinusitis and otitis media to severe ones such as pneumonia and meningitis, often necessitating hospital care. The heightened incidence of these diseases stems from factors including decreased vaccination during the COVID-19 pandemic, elevated risks for those with chronic health issues, and a rise in respiratory infections post-social restriction relaxations. Pneumovax 23 offers protection by immunizing against 23 strains of streptococcus pneumoniae, thereby lowering the risk of infections like pneumonia, meningitis, and bacteremia. An example illustrating this trend is provided by the Office for Health Improvement and Disparities, a UK government body, which reported in June 2025 that emergency hospital admissions for pneumonia in England increased by 16% in the financial year ending 2024 compared to the previous year, reaching a rate of 430 per 100,000 people and totaling approximately 252,912 admissions. Consequently, the global rise in pneumococcal disease incidence is a primary driver for the Pneumovax 23 market’s growth.

What Segment Classifications Make Up The Pneumovax 23 Market?

The pneumovax 23 market covered in this report is segmented –

1) By Formulation: Pneumococcal Polysaccharide Vaccine (PPV), Pneumococcal Conjugate Vaccine (PCV)

2) By Clinical Indication: Pneumococcal Disease Prevention

3) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies

Which Key Market Players Are Investing In Expansion And Innovation Within The Pneumovax 23 Market?

Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pneumovax-23-global-market-report

Which Regions Are Poised For Strategic Growth In The Pneumovax 23 Market?

North America was the largest region in the pneumovax 23 market in 2025. The regions covered in the pneumovax 23 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pneumovax 23 Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20333&type=smp

Browse Through More Reports Similar to the Global Pneumovax 23 Market 2026, By The Business Research Company

Commercial P2P Cdn Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-p2p-cdn-global-market-report

Polybutylene Terephthalate Pbt Market Report 2026

https://www.thebusinessresearchcompany.com/report/polybutylene-terephthalate-pbt-global-market-report

Biopreservation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopreservation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795